BidaskClub downgraded shares of Selecta Biosciences (NASDAQ:SELB) from a buy rating to a hold rating in a research note published on Friday.
Other analysts also recently issued research reports about the company. Stifel Nicolaus started coverage on Selecta Biosciences in a research note on Friday, September 14th. They issued a buy rating and a $24.00 price target on the stock. Canaccord Genuity reissued a buy rating and issued a $40.00 price target on shares of Selecta Biosciences in a research note on Thursday, June 28th. Janney Montgomery Scott started coverage on Selecta Biosciences in a research note on Wednesday, June 27th. They issued a buy rating and a $33.00 price target on the stock. Mizuho reissued a buy rating and issued a $30.00 price target on shares of Selecta Biosciences in a research note on Thursday, August 9th. Finally, ValuEngine raised Selecta Biosciences from a sell rating to a hold rating in a research note on Thursday, July 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. Selecta Biosciences currently has a consensus rating of Hold and a consensus price target of $27.40.
Shares of Selecta Biosciences stock opened at $13.86 on Friday. The firm has a market cap of $348.26 million, a P/E ratio of -4.33 and a beta of -3.47. Selecta Biosciences has a 12 month low of $7.95 and a 12 month high of $24.02. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.96 and a current ratio of 4.96.
Selecta Biosciences (NASDAQ:SELB) last released its quarterly earnings results on Wednesday, August 8th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.16). On average, analysts expect that Selecta Biosciences will post -3.07 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its stake in shares of Selecta Biosciences by 43.7% in the 2nd quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock valued at $222,000 after purchasing an additional 5,103 shares during the period. Proxima Capital Management LLC bought a new position in shares of Selecta Biosciences in the 2nd quarter valued at about $1,075,000. BlackRock Inc. grew its holdings in shares of Selecta Biosciences by 1.6% in the 1st quarter. BlackRock Inc. now owns 629,978 shares of the company’s stock valued at $6,420,000 after acquiring an additional 9,749 shares in the last quarter. DRW Securities LLC bought a new position in shares of Selecta Biosciences in the 1st quarter valued at about $122,000. Finally, Wasatch Advisors Inc. grew its holdings in shares of Selecta Biosciences by 9.2% in the 2nd quarter. Wasatch Advisors Inc. now owns 235,625 shares of the company’s stock valued at $3,122,000 after acquiring an additional 19,803 shares in the last quarter. 48.74% of the stock is currently owned by hedge funds and other institutional investors.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Story: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.